ENYO Pharma ENYO announced that it has received clearance of its Investigational New Drug IND application from the U.S. Food and Drug Administration FDA to initiate a Phase 2 clinical study of Vonafexor a highly selective FXR agonist for the treatment of Alport Syndrome.
ENYO Pharma Announces a €39 Million Series C Financing and FDA Clearance to Advance Vonafexor in a Phase 2 Clinical Trial for Patients With Alport Syndrome finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
LSP and Bpifrance, through its InnoBio 2 Fund, co-led international investor syndicate Egle Therapeutics SAS (Egle), an emerging biotechnology company focused on developing First-In-Class immunotherapies